Phase I/Phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia

Journal of Clinical Oncology

Volumn 34, Issue 36, 2016, Pages 4381-4389

  Von Stackelberg, Arend ^a   Locatelli, Franco ^f   Zugmaier, Gerhard ^b   Handgretinger, Rupert ^c   Trippett, Tanya M ^m   Rizzari, Carmelo ^h   Bader, Peter ^d   O'brien, Maureen M ⁿ   Brethon, Benôit ^j   Bhojwani, Deepa ^o   Schlegel, Paul Gerhardt ^e   Borkhardt, Arndt ^f,g   Rheingold, Susan R ^q   Cooper, Todd Michael ^r   Zwaan, Christian M ^l   Barnette, Phillip ^s   Messina, Chiara ^h,i   Michel, Ǵerard ^k   Dubois, Steven G ^t   Hu, Kuolung ^p   Zhu, Min ^p   Whitlock, James A ^v   Gore, Lia ^u   more..

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Amgen Research GmbH   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d GOETHE UNIVERSITY   (Germany)

^e UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^f HEINRICH HEINE UNIVERSITY   (Germany)

^g UNIVERSITY OF PAVIA   (Italy)

^h SAN GERARDO HOSPITAL   (Italy)

ⁱ UNIVERSITY OF PADOVA   (Italy)

^j HÔPITAL ROBERT DEBRÉ   (France)

^k TIMONE HOSPITAL   (France)

^l SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^m MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁿ CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^o CHILDREN S HOSPITAL LOS ANGELES   (United States)

^p AMGEN INC   (United States)

^q CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^r SEATTLE CHILDREN S HOSPITAL   (United States)

^s PRIMARY CHILDREN'S MEDICAL CENTER   (United States)

^t HARVARD MEDICAL SCHOOL   (United States)

^u UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^v HOSPITAL FOR SICK CHILDREN   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BLINATUMOMAB; DEXAMETHASONE; HYDROXYUREA; TOCILIZUMAB; ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAIN HEMORRHAGE; CANCER IMMUNOTHERAPY; CHILD; CHILDHOOD LEUKEMIA; CONFUSION; CONSOLIDATION CHEMOTHERAPY; CONTINUOUS INFUSION; CYTOKINE RELEASE SYNDROME; CYTOPENIA; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL HEMORRHAGE; GROUPS BY AGE; HEADACHE; HEART ARREST; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERTENSION; HYPOKALEMIA; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; MUSCLE HYPOTONIA; MUSCLE WEAKNESS; MYCOSIS; NAUSEA; NEURALGIA; NEUROLOGIC DISEASE; NEUTROPENIA; NEUTROPHIL COUNT; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROPHYLAXIS; RECOMMENDED DRUG DOSE; RESPIRATORY FAILURE; SCHOOL CHILD; SEIZURE; SEPSIS; SOMNOLENCE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT INTERRUPTION; TREMOR; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; INTRAVENOUS DRUG ADMINISTRATION; MORTALITY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SINGLE BLIND PROCEDURE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ADOLESCENT; ANTIBODIES, BISPECIFIC; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MAXIMUM TOLERATED DOSE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SINGLE-BLIND METHOD; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 85009814489     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.67.3301     Document Type: Article

References (31)

1. World Health Organization: 4.1 Incidence of Childhood Leukaemia, an ENHIS Fact Sheet. Copenhagen, Denmark, World Health Organization, 2009. http://www.euro.who.int/en/health-topics/noncommunicable-diseases/cancer/publications/2009/4.1-incidence-of-childhood-leukaemia, -an-enhisfact-sheet.
2. Möricke A, Zimmermann M, Reiter A, et al: Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 24:265-284, 2010.
3. Pui CH, Robison LL, Look AT: Acute lymphoblastic leukaemia. Lancet 371:1030-1043, 2008.
4. Parker C, Waters R, Leighton C, et al: Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): An open-label randomised trial. Lancet 376:2009-2017, 2010.
5. Tallen G, Ratei R, Mann G, et al: Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: Results of trial ALL-REZ BFM 90. J Clin Oncol 28:2339-2347, 2010.
6. Ko RH, Ji L, Barnette P, et al: Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: A Therapeutic Advances in Childhood Leukemia Consortium study. J Clin Oncol 28:648-654, 2010.
7. von Stackelberg A, Völzke E, Kühl JS, et al: Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: A retrospective analysis of the ALL-REZ BFM Study Group. Eur J Cancer 47: 90-97, 2011.
8. Tedder TF, Inaoki M, Sato S: The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. Immunity 6:107-118, 1997.
9. Hasegawa M, Fujimoto M, Poe JC, et al: CD19 can regulate B lymphocyte signal transduction independent of complement activation. J Immunol 167:3190-3200, 2001.
10. von Stackelberg A: Monoclonal antibodies in paediatric acute lymphoblastic leukemia, in Saha V, Kearns P (eds): New Agents for the Treatment of Acute Lymphoblastic Leukaemia. New York, NY, Springer Science and Business Media, 2011, pp 221- 271.
11. Dreier T, Lorenczewski G, Brandl C, et al: Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer 100:690-697, 2002.
12. Hoffmann P, Hofmeister R, Brischwein K, et al: Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific singlechain antibody construct. Int J Cancer 115:98-104, 2005.
13. Topp MS, Gökbuget N, Stein AS, et al: Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: A multicentre, single-arm, phase 2 study. Lancet Oncol 16:57-66, 2015.
14. National Cancer Institute: Common Terminology Criteria for Adverse Events v4.03. Bethesda, MD, National Institutes of Health, 2010.
15. Skolnik JM, Barrett JS, Jayaraman B, et al: Shortening the timeline of pediatric phase I trials: The rolling six design. J Clin Oncol 26:190-195, 2008.
16. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989.
17. Teachey DT, Rheingold SR, Maude SL, et al: Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 121: 5154-5157, 2013.
18. Topp MS, Gökbuget N, Zugmaier G, et al: Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 120: 5185-5187, 2012.
19. Topp MS, Gökbuget N, Zugmaier G, et al: Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol 32:4134-4140, 2014.
20. Topp MS, Kufer P, Gökbuget N, et al: Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 29:2493-2498, 2011.
21. Goekbuget N, Dombret H, Bonifacio M, et al: BLAST: A confirmatory, single-arm, phase 2 study of blinatumomab, a bispecific T-cell engager (BiTE®) antibody construct, in patients with minimal residual disease B-precursor acute lymphoblastic leukemia (ALL). Blood 124:379, 2014 (abstr).
22. Zugmaier G, Nagorsen D, Klinger M, et al: Identification of a predictive factor for reversible neurological adverse events in a subset of Non-Hodgkin lymphoma patients treated with CD19-specific BiTE® antibody blinatumomab. Blood 114:4793, 2009 (abstr).
23. Handgretinger R, Zugmaier G, Henze G, et al: Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia. Leukemia 25:181-184, 2011.
24. Schlegel P, Lang P, Zugmaier G, et al: Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab. Haematologica 99:1212-1219, 2014.
25. Uckun FM, Jaszcz W, Ambrus JL, et al: Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood 71:13-29, 1988.
26. Zugmaier G, Topp MS, Alekar S, et al: Longterm follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia. Blood Cancer J 4:244, 2014.
27. Raetz EA, Cairo MS, Borowitz MJ, et al: Reinduction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2. Pediatr Blood Cancer 62:1171-1175, 2015.
28. Kantarjian H, Thomas D, Jorgensen J, et al: Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: A phase 2 study. Lancet Oncol 13:403-411, 2012.
29. Grupp SA, Kalos M, Barrett D, et al: Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368:1509-1518, 2013.
30. Maude SL, Teachey DT, Porter DL, et al: CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood 125: 4017-4023, 2015.
31. Sotillo E, Barrett DM, Black KL, et al: Convergence of acquiredmutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov 5:1282-1295, 2015.